Evolus (NASDAQ:EOLS) Stock Price Down 6% on Insider Selling

Evolus, Inc. (NASDAQ:EOLSGet Free Report)’s stock price was down 6% on Friday following insider selling activity. The company traded as low as $11.52 and last traded at $11.65. Approximately 211,537 shares changed hands during trading, a decline of 65% from the average daily volume of 605,420 shares. The stock had previously closed at $12.40.

Specifically, insider David Moatazedi sold 155,278 shares of Evolus stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $12.92, for a total value of $2,006,191.76. Following the completion of the sale, the insider now owns 533,349 shares in the company, valued at approximately $6,890,869.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director David N. Gill sold 3,643 shares of the stock in a transaction on Monday, May 13th. The stock was sold at an average price of $12.72, for a total value of $46,338.96. Following the transaction, the director now directly owns 40,682 shares of the company’s stock, valued at approximately $517,475.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider David Moatazedi sold 155,278 shares of Evolus stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $12.92, for a total value of $2,006,191.76. Following the completion of the transaction, the insider now directly owns 533,349 shares in the company, valued at $6,890,869.08. The disclosure for this sale can be found here. Insiders have sold 224,406 shares of company stock worth $2,934,339 over the last quarter. 6.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on EOLS. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Evolus in a research report on Wednesday, May 8th. HC Wainwright restated a “buy” rating and issued a $27.00 target price on shares of Evolus in a research note on Tuesday, May 21st.

Get Our Latest Report on EOLS

Evolus Stock Performance

The company has a 50 day moving average price of $12.72 and a 200-day moving average price of $12.20. The company has a market cap of $731.79 million, a P/E ratio of -11.12 and a beta of 1.32. The company has a quick ratio of 2.96, a current ratio of 3.21 and a debt-to-equity ratio of 6.54.

Evolus (NASDAQ:EOLSGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $59.33 million for the quarter, compared to analyst estimates of $58.78 million. Equities analysts expect that Evolus, Inc. will post -0.61 EPS for the current fiscal year.

Institutional Trading of Evolus

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC bought a new stake in shares of Evolus in the 3rd quarter worth approximately $357,000. Barclays PLC raised its position in shares of Evolus by 24.5% during the third quarter. Barclays PLC now owns 19,794 shares of the company’s stock worth $181,000 after purchasing an additional 3,889 shares during the period. Swiss National Bank lifted its holdings in shares of Evolus by 1.8% during the third quarter. Swiss National Bank now owns 93,800 shares of the company’s stock valued at $857,000 after purchasing an additional 1,700 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in shares of Evolus in the third quarter worth about $263,000. Finally, Kestra Advisory Services LLC increased its position in shares of Evolus by 18.5% in the third quarter. Kestra Advisory Services LLC now owns 16,356 shares of the company’s stock worth $149,000 after acquiring an additional 2,550 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

About Evolus

(Get Free Report)

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Read More

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.